Control of atrial defibrillation therapy based on hemodynamic sensor feedback
First Claim
Patent Images
1. A method comprising:
- detecting atrial fibrillation;
measuring hemodynamic performance during atrial fibrillation; and
enabling therapy based on the measured hemodynamic performance;
wherein enabling therapy comprises determining whether hemodynamic compromise is present based on the hemodynamic performance during fibrillation, enabling the therapy when hemodynamic compromise is present, and disabling therapy when hemodynamic compromise is not present.
1 Assignment
0 Petitions
Accused Products
Abstract
Control of defibrillation therapy delivered by implantable medical devices (IMDs) using hemodynamic sensor feedback is disclosed. The hemodynamic sensor feedback allows for increased control over application of atrial defibrillation therapy. Specifically, the therapy is delivered when a fibrillation episode results in a discrete loss of hemodynamic function. Defibrillation therapy is thus withheld for hemodynamically benign arrhythmias.
-
Citations
37 Claims
-
1. A method comprising:
-
detecting atrial fibrillation; measuring hemodynamic performance during atrial fibrillation; and enabling therapy based on the measured hemodynamic performance; wherein enabling therapy comprises determining whether hemodynamic compromise is present based on the hemodynamic performance during fibrillation, enabling the therapy when hemodynamic compromise is present, and disabling therapy when hemodynamic compromise is not present. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A system for controlling application of therapy to a heart, the system comprising:
-
a first sensor that detects atrial fibrillation; a second sensor that measures hemodynamic performance during fibrillation; and a processor that is programmed whether hemodynamic compromise is present based on the hemodynamic performance during atrial fibrillation, and enables delivery of therapy when hemodynamic compromise is present and disables delivery of therapy when hemodynamic compromise is not present. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
-
28. A system for controlling application of therapy to a heart, the system comprising:
-
means for detecting atrial fibrillation; means for measuring hemodynamic performance during atrial fibrillation; means for determining whether hemodynamic compromise is present based on the measured hemodynamic performance; means for enabling delivery of therapy when hemodynamic compromise is present; and means for disabling delivery of therapy when hemodynamic compromise is not present. - View Dependent Claims (29, 30, 31)
-
-
32. A method of controlling application of therapy, the method comprising:
-
detecting atria fibrillation programming a time period to automatically deliver the therapy; measuring hemodynamic performance at the programmed time period; determining whether hemodynamic compromise is present at the programmed time period based on the measured hemodynamic performance; and enabling delivery of therapy when hemodynamic compromise is present; and disabling delivery of therapy when hemodynamic compromise is not present. - View Dependent Claims (33, 34, 35)
-
-
36. A computer-readable medium containing instructions for causing a processor to:
-
detect atrial fibrillation; measure hemodynamic performance detect atrial fibrillation; measure hemodynamic performance during normal sinus rhythm; compare the hemodynamic performance during fibrillation to the hemodynamic performance during normal sinus rhythm to determine whether a change in hemodynamic performance has occurred; detecting presence of hemodynamic compromise when the change exceeds a threshold; enable delivery of therapy when hemodynamic compromise is present; and disable delivery of therapy when hemodynamic compromise is not present.
-
-
37. A method comprising:
-
detecting atrial fibrillation; measuring hemodynamic performance during atrial fibrillation; and enabling therapy based on the measured hemodynamic performance; wherein enabling therapy comprises determining whether hemodynamic compromise is present based on the hemodynamic performance during fibrillation, enabling the therapy when hemodynamic compromise is present, and disabling therapy when hemodynamic compromise is not present, and wherein determining whether hemodynamic compromise is present further comprises; measuring a hemodynamic performance baseline during normal sinus rhythm; comparing the hemodynamic performance during fibrillation to the hemodynamic performance baseline to determine whether a change in hemodynamic performance has occurred; and determining presence of hemodynamic compromise when the change exceeds a threshold for at least a predetermined minimum time period.
-
Specification